Sanofi Expands Decade-Long Partnership with Medidata to Accelerate Clinical Trial Development
核心洞察
Sanofi and Medidata announced an expansion of their 10-plus-year collaboration to leverage AI-embedded platform solutions across clinical workflows.
The partnership will utilize Medidata's Patient, Data, and Study Experiences to streamline operations, enhance data quality, and reduce costs and delays in clinical trials.
Sanofi will employ Medidata's decentralized clinical trial expertise along with strategic consulting and end-to-end operational support to expedite therapy development.
Sanofi and Medidata, a Dassault Systèmes (搜索) brand, announced on October 23, 2025, an expansion of their decade-long partnership to enhance clinical research capabilities and accelerate the development of new therapies. The expanded collaboration will leverage Medidata's AI-embedded platform solutions to streamline clinical trial operations and improve patient care globally.
Enhanced Platform Integration
The new agreement centers on the implementation of Medidata Patient, Data, and Study Experiences, which address the fragmented nature of traditional life sciences tools. These AI-embedded, platform-based solutions are designed to unify trial processes across clinical workflows, reduce operational silos, and minimize both costs and delays in drug development.
"Sanofi and Medidata have worked together for a decade within clinical research, including a collaboration in 2024," said Gaelan Ritter, global head of digital clinical development at Sanofi. "With this broadened relationship, we will continue harnessing the power of AI, optimizing our clinical trials, and ultimately expediting the delivery of groundbreaking medicines."
Decentralized Trial Capabilities
As part of the enterprise agreement, Sanofi will utilize Medidata's expertise in decentralized clinical trials, a growing area of focus in modern drug development. Medidata will provide strategic consulting and comprehensive operational support to help Sanofi further streamline its research processes and enhance study execution.
The partnership builds on both organizations' shared vision to boost innovation in clinical studies and promote improved health outcomes for patients worldwide. By combining Medidata's technological capabilities with Sanofi's pharmaceutical expertise, the collaboration aims to advance studies with greater precision and clinical impact.
Strategic Clinical Development Focus
Lisa Moneymaker, chief strategy officer at Medidata, emphasized the complexity of clinical development and the need for strategic partnerships. "Clinical development is complex, and biopharma companies demand a strategic partner who can help them enhance data quality, improve study design, and elevate patient care," she said. "Through our alliance, Sanofi can leverage our unified solutions, specifically mapped out to meet their core needs, to simplify execution and accelerate the entire clinical development process."
Technology Platform Advantages
Medidata's platform brings significant scale to the partnership, with the company celebrating 25 years of technological innovation across more than 36,000 trials involving 11 million patients. The platform serves more than 1 million registered users across approximately 2,300 customers, providing one of the largest clinical trial datasets in the industry.
The expanded partnership represents a strategic move by both companies to address the increasing complexity of modern clinical trials while leveraging artificial intelligence and unified platform solutions to improve efficiency and patient outcomes in pharmaceutical research and development.